Lundkvist J, Kastäng F, Kobelt G
i3innovus, Stockholm, Sweden.
Eur J Health Econ. 2008 Jan;8 Suppl 2:S49-60. doi: 10.1007/s10198-007-0088-8.
As part of the study "The burden of rheumatoid arthritis and patient access to treatment", this paper reviews evidence on the health burden of rheumatoid arthritis (RA) in terms of morbidity (DALYs), mortality (% of deaths attributable to RA) and quality of life (utility and loss of QALYs), as well as the economic impact on society. Based on available literature on the prevalence and the cost of RA, combined with economic indicators, the annual cost per patient as well as the total national cost is estimated for Europe and North America (Canada and the United States), as well as Australia, Turkey, the Russian Federation and South Africa. Total costs to society were estimated at
作为“类风湿性关节炎负担与患者治疗可及性”研究的一部分，本文回顾了关于类风湿性关节炎（RA）在发病率（伤残调整生命年）、死亡率（归因于RA的死亡百分比）和生活质量（效用和质量调整生命年损失）方面的健康负担证据，以及对社会的经济影响。基于关于RA患病率和成本的现有文献，结合经济指标，估算了欧洲、北美（加拿大和美国）以及澳大利亚、土耳其、俄罗斯联邦和南非每位患者的年度成本以及国家总成本。据估计，欧洲社会的总成本为453亿欧元，美国为416亿欧元。与其他疾病相比，效用得分处于最低水平。
